α-Ethyl-α-methyl-glutarimid | 3206-77-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: α-Ethyl-α-methyl-glutarimid
• 英文别名: 3-ethyl-3-methyl-piperidine-2,6-dione；3-ethyl-3-methylpiperidine-2,6-dione
• CAS: 3206-77-7
• 化学式: C₈H₁₃NO₂
• 分子量: 155.197
• InChiKey: NTVHPNIYLWFSOL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (-)-4-Cyano-4-ethyl-4-methyl-butyric acid 、 溶剂黄146 、 盐酸 生成 α-Ethyl-α-methyl-glutarimid
  参考文献：
  名称：

  KNABE, J.;REISCHIG, D., ARCH. PHARM., 1984, 317, N 4, 353-362

  摘要：

  DOI：

文献信息

• Compositions and methods for treating multiple myeloma
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10302644B2

  公开（公告）日：2019-05-28

  The invention provides, inter alia, methods of prognosing the survival of a multiple myeloma patient based levels of TP53RK in multiple myeloma cells of the patient. Also provided are methods of screening for therapeutic agents for treating multiple myeloma based on their ability to decrease TP53RK levels or activity in a patient with multiple myeloma.

  本发明特别提供了根据多发性骨髓瘤患者细胞中 TP53RK 的水平预测其生存期的方法。本发明还提供了根据TP53RK降低多发性骨髓瘤患者体内TP53RK水平或活性的能力筛选治疗多发性骨髓瘤的治疗剂的方法。
• 6-membered uracil isosteres
  申请人：CV6 Therapeutics (NI) Limited

  公开号：US11174271B2

  公开（公告）日：2021-11-16

  Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

  本文提供了 dUTP 酶抑制剂、包含此类化合物的组合物以及使用此类化合物和组合物的方法。
• COMPOSITIONS AND METHODS FOR TREATING MULTIPLE MYELOMA
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US20170356917A1

  公开（公告）日：2017-12-14

  The invention provides, inter alia, methods of prognosing the survival of a multiple myeloma patient based levels of TP53RK in multiple myeloma cells of the patient. Also provided are methods of screening for therapeutic agents for treating multiple myeloma based on their ability to decrease TP53RK levels or activity in a patient with multiple myeloma.
• 6-MEMBERED URACIL ISOSTERES
  申请人：CV6 Therapeutics (NI) Limited

  公开号：US20190270756A1

  公开（公告）日：2019-09-05

  Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.
• US4423049A
  申请人：——

  公开号：US4423049A

  公开（公告）日：1983-12-27